Roivant Sciences Ltd. (ROIV): Price and Financial Metrics
GET POWR RATINGS... FREE!
ROIV POWR Grades
- Sentiment is the dimension where ROIV ranks best; there it ranks ahead of 88.22% of US stocks.
- The strongest trend for ROIV is in Stability, which has been heading down over the past 177 days.
- ROIV's current lowest rank is in the Momentum metric (where it is better than 7.21% of US stocks).
ROIV Stock Summary
- ROIVANT SCIENCES LTD's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than only 11.22% of US listed stocks.
- With a price/sales ratio of 121.69, ROIVANT SCIENCES LTD has a higher such ratio than 97.72% of stocks in our set.
- In terms of twelve month growth in earnings before interest and taxes, ROIVANT SCIENCES LTD is reporting a growth rate of 122.57%; that's higher than 88.45% of US stocks.
- If you're looking for stocks that are quantitatively similar to ROIVANT SCIENCES LTD, a group of peers worth examining would be RAMP, COUR, ASAN, S, and HCAT.
- To dig deeper into the stock's financial statements, go to ROIV's page on browse-edgar?action=getcompany&CIK=0001635088.
ROIV Valuation Summary
- In comparison to the median Healthcare stock, ROIV's price/sales ratio is 2489.36% higher, now standing at 121.7.
- Over the past 30 months, ROIV's price/sales ratio has gone up 112.6.
Below are key valuation metrics over time for ROIV.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| ROIV | 2023-03-24 | 121.7 | 5.5 | -4.2 | -3.4 |
| ROIV | 2023-03-23 | 122.9 | 5.5 | -4.3 | -3.4 |
| ROIV | 2023-03-22 | 127.9 | 5.8 | -4.4 | -3.6 |
| ROIV | 2023-03-21 | 134.4 | 6.1 | -4.7 | -3.8 |
| ROIV | 2023-03-20 | 153.2 | 6.9 | -5.3 | -4.5 |
| ROIV | 2023-03-17 | 153.0 | 6.9 | -5.3 | -4.5 |
ROIV's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- ROIV has a Quality Grade of C, ranking ahead of 35.69% of graded US stocks.
- ROIV's asset turnover comes in at 0.115 -- ranking 251st of 681 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows ROIV's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-03-31 | 0.115 | 0.914 | -3.951 |
ROIV Stock Price Chart Interactive Chart >
ROIV Price/Volume Stats
| Current price | $7.31 | 52-week high | $10.00 |
| Prev. close | $7.69 | 52-week low | $2.52 |
| Day low | $7.26 | Volume | 2,154,000 |
| Day high | $7.85 | Avg. volume | 2,917,787 |
| 50-day MA | $8.07 | Dividend yield | N/A |
| 200-day MA | $5.77 | Market Cap | 5.54B |
Roivant Sciences Ltd. (ROIV) Company Bio
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
Latest ROIV News From Around the Web
Below are the latest news stories about ROIVANT SCIENCES LTD that investors may wish to consider to help them evaluate ROIV as an investment opportunity.
Covant and Boehringer Ingelheim Collaborate to Develop a Novel ADAR1 Inhibitor for Use in Cancer PatientsBOSTON, March 28, 2023 (GLOBE NEWSWIRE) -- Covant Therapeutics, an innovative covalent drug discovery company, has entered into an exclusive research collaboration and worldwide licensing agreement with Boehringer Ingelheim covering Covant’s ADAR1 program. The companies jointly aim to develop a novel small molecule immunotherapy targeting ADAR1 to transform the lives of cancer patients. Covant significantly accelerates drug discovery for challenging targets like ADAR1 by using its industry-leadi |
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare SectorTo play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy. |
Roivant Reports Positive Topline Results from ADORING 2 Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% Once Daily in Adults and Children as Young as 2 Years Old46.4% of subjects receiving VTAMA cream, 1% achieved the primary endpoint of Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-ADTM) response of clear (0) or almost clear (1) with at least a 2-grade improvement from baseline at Week 8, versus 18.0% on vehicle (P<0.0001)All secondary endpoints were met with a high degree of statistical significance, including 59.1% of subjects treated with VTAMA cream who achieved the key secondary endpoint of EASI75 (P<0.0001)Meaningful impact |
Roivant to Host Investor Call at 8:00 AM ET on Wednesday, March 15 to Review Results from ADORING 2 Phase 3 Trial in Atopic DermatitisBASEL, Switzerland and LONDON and NEW YORK and BOSTON, March 14, 2023 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV) today announced that it will host a live investor call and webcast at 8:00 AM ET on Wednesday, March 15 to review topline results from the ADORING 2 study, one of two replicate Phase 3 studies in atopic dermatitis. To access the call by phone, please register online using this registration link. A webcast of the call will also be available under “Events & Presentations” in th |
Proteovant Therapeutics to Present Preclinical Data from Estrogen Receptor and IKZF2 Protein Degrader ProgramsPVTX-321 and PVTX-405 Achieve Development Candidate NominationNEW YORK, March 14, 2023 (GLOBE NEWSWIRE) -- Proteovant Therapeutics, a Roivant Sciences (Nasdaq: ROIV) company leveraging the process of protein degradation to discover and develop transformative medicines for the treatment of patients with life-altering diseases, today announced it will present data on PVTX-321, an estrogen receptor degrader, at the Protein Degradation & Targeting Undruggables Congress USA, March 15-16 in Boston and |
ROIV Price Returns
| 1-mo | -7.70% |
| 3-mo | -8.51% |
| 6-mo | 127.02% |
| 1-year | 47.98% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -8.51% |
| 2022 | -20.73% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...